Psych Capital PLC - London-based media firm and investor, specialising in psychedelic medicines - Reports that the University of Tel-Aviv's Institute for Integrative Psychedelic Research, IPR-TLV, has awarded an additional grant to a Phase 1 POC study of psilocybin-assisted therapy for anorexia nervosa patients. Study is being conducted by the Department of Eating Disorders at the Sheba Medical Center in Tel HaShomer, near Tel Aviv. Its exclusive commercial partner is Ontario, Canada-based medical therapy developer Shortwave Pharma Inc, which was acquired by Psych Capital late last year and has operations based in Israel. Psych says the grant "demonstrates the growing acceptance and integration of research in psychedelic assisted treatment in addressing critically unmet mental health conditions."
Psych Capital Chief Executive Officer Rivki Stern comments: "Despite the on-going war in Israel, and perhaps because of it, we see a growing consideration of innovative treatments for mental health conditions, which are known to be exacerbated in war and crisis environments. We expect this to advance regulatory acceptance of psychedelic based medicine for mental health issues in Israel."
Current stock price: 2.95 pence
12-month change: down 24%
By Emma Curzon, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
